$HINDVyome Holdings, Inc

📅 Upcoming

🕒 Recent(90d)

News

• Mirum reports Phase 3 victory for acquired hepatitis D med
  Mirum Pharmaceuticals’ recently purchased chronic hepatitis delta treatment has scored a Phase 3 win, adding momentum behind the company’s pipeline and commercial future. More than half of patients…
  endpoints · 6d ago
• Key research behind orexin and narcolepsy wins Lasker Award
  The path to understanding a common sleep disorder started with lab banter and traveled through mice, dogs and more recently, the flu virus. Now, the science behind narcolepsy has won both a Breakth…
  endpoints · 25d ago
• Trump is taking credit for lower list prices. But a Biden-era law did a lot of the heavy lifting
  List prices for brand-name drugs have declined significantly in 2026. But the reasons behind it may have more to do with a Biden-era law than any of the Trump administration's recent initiatives, e…
  endpoints · 1mo ago
• 'Incorrect and misleading' data prompted decision to pull Tavneos in Europe
  European regulators on Thursday explained last week's decision to pull Amgen's rare disease drug Tavneos from the market there, detailing their skepticism about the data. In new documents posted Th…
  endpoints · 1mo ago
• What’s behind the proposed pullback on remote patient monitoring
  Companies that help doctors keep tabs on their patients at home are freaking out after Medicare's proposal last week to gut remote patient monitoring, or RPM. The plan is a total about-face from th…
  endpoints · 2mo ago
• House lawmakers back trade probe of China biotech, sequencing
  At least 10 House lawmakers are backing a US trade panel’s probe of China’s biotech sector and related pricing practices, encouraging future executive action. In a letter sent to Secretary of the U…
  endpoints · 2mo ago
• Former Akero team announces new I&I company, Avere, with China drug
  Everything around China biotech really does seem to be speeding up. On Tuesday, the former executive team behind Akero Therapeutics unveiled a new company, a pipeline drug from China and a reverse…
  endpoints · 2mo ago
• HHS lays groundwork for new FDA rule on releasing CRLs
  The Trump administration is pushing the FDA to cement the details behind its proactive public release of rejection letters sent to pharma companies. The push comes as an HHS spokesperson confirmed…
  endpoints · 2mo ago
• Eli Lilly's TuneLab hits 100 members, adding Chai's AI models
  The leader behind TuneLab, Eli Lilly's first-of-its-kind AI initiative, had no idea what to expect when it launched. Lilly was trying something new by effectively offering biotechs free access to s…
  endpoints · 3mo ago
• Post-Hoc Live: How much is everyone in biopharma getting paid?
  The one law of CEO pay packages: They keep getting bigger. Yesterday, we published the first installment of Endpoints News’ annual biopharma compensation project. Following our analysis of the indu…
  endpoints · 3mo ago